HK Stock Market Move | TRIP.COM-S (09961) falls more than 4% during trading, with a net profit of 4.3 billion yuan in the fourth quarter of last year. The CEO and director both resign.
Ctrip Group-S (09961) fell 4% in the afternoon, but the decline has narrowed. As of press time, it is down 2.75% to 402.4 Hong Kong dollars, with a turnover of 2.13 billion Hong Kong dollars.
Trip.com-S (09961) fell by 4% in the afternoon, but the decline has since narrowed. As of the close of trading, it was down 2.75% at HK$402.4, with a turnover of HK$2.13 billion.
On the news front, on February 26, Trip.com Group announced its unaudited financial performance for the fourth quarter and full year of 2025. In the fourth quarter of 2025, Trip.com Group's net operating revenue was 15.4 billion RMB, a 21% increase year-on-year; net operating revenue decreased by 16% quarter-on-quarter; net profit was 4.3 billion RMB, compared to 2.2 billion RMB in the same period of 2024 and 19.9 billion RMB in the previous quarter. In addition, Trip.com also announced a series of director changes, which took effect from February 25, 2026. The announcement stated that Fan Min had resigned from the positions of director and president of the company, and Ji Qi had resigned from the position of director. At the same time, the company announced the appointment of Wu Yihong and Xiao Yang as new independent directors.
It is worth noting that in the performance announcement, Trip.com Group stated that in January 2026, the company received a notice of investigation from the State Administration for Market Regulation and learned that an investigation had been initiated under the Anti-Monopoly Law of the People's Republic of China. The investigation is still ongoing, and the company is fully cooperating with the State Administration for Market Regulation. The company cannot predict the status and results of the investigation at this time, and will provide further updates after the investigation is concluded. The company's business operations remain normal.
Related Articles

Fuan Pharmaceutical (300194.SZ) subsidiary has received approval for a chemical raw material drug to be listed.

Apple Inc. (AAPL.US) is in intensive discussions with three major banks in India, planning to launch Apple Pay in the market with a population of 1.4 billion.

Bank of America Merrill Lynch: Reiterated KUAISHOU-W (01024) "Buy" rating with a target price of HK$94.
Fuan Pharmaceutical (300194.SZ) subsidiary has received approval for a chemical raw material drug to be listed.

Apple Inc. (AAPL.US) is in intensive discussions with three major banks in India, planning to launch Apple Pay in the market with a population of 1.4 billion.

Bank of America Merrill Lynch: Reiterated KUAISHOU-W (01024) "Buy" rating with a target price of HK$94.

RECOMMEND

Robot Concept Hong Kong Stocks Retreat After Spring Gala Rally As 2026 Emerges As Pivotal Year For Mass Production And Commercialization
25/02/2026

Hong Kong IPO Fundraising Surges Tenfold At Start Of Year As 110 A‑Share Companies Queue For Listings
25/02/2026

AI Iteration Risks Surface As Hong Kong Market Diverges; Low‑Valuation, High‑Dividend Legacy Stocks Attract Capital As Safe Havens
25/02/2026


